C2N at AD/PD 2025 in Vienna
C2N Diagnostics, LLC, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s and Parkinson’s Diseases Conference in Vienna, Austria April 1 – 5.
C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AD/PD. Please join us in Vienna and be among the first to learn about exciting new data for the Precivity™ line of blood tests.
We encourage you to click this link to schedule a meeting with our team.
All sessions and posters will be held at the Austria Center Vienna.
12 sessions and 6 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include:
Presentations by C2N Executives
Tuesday, April 1
9:50 – 10:55
ADDF DxA Summit – Invite Only Event
Focusing on the Current Diagnostic Landscape for Alzheimer’s, From Development to Implementation
Presenter: Joel Braunstein (United States of America)
Wednesday, April 2
13:00 – 13:30
Transforming Alzheimer’s Disease Diagnosis with The PrecivityAD2™ Blood Test: Seeking to Establish a New Clinical Care Standard for Patients with Memory Impairment (ID 3284)
Room: Exhibition/Product Theater
Presenter: Joel Braunstein (United States of America)
Saturday, April 5
12:25 – 12:40
PRECIVITYAD2 TEST ACCURATELY IDENTIFIES BRAIN AMYLOID AND TAU PATHOLOGY IN ADNI PARTICIPANTS ENROLLED IN THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH STUDY. (ID 2534)
Room: Hall F2
Presenter: Philip B. Verghese (United States of America)
Tuesday, April 1
15:00 – 15:15
PLASMA MTBR-TAU243 IS SPECIFICALLY ASSOCIATED WITH TAU TANGLE PATHOLOGY IN ALZHEIMER’S DISEASE (ID 3014)
Room: Hall A
Presenter: Kanta Horie (United States of America)
Wednesday, April 2
9:10 – 9:25
QUANTIFYING BRAIN HEALTH AS A PREDICTOR OF ALZHEIMER’S RISK, DISEASE PROGRESSION, AND TARGET FOR PREVENTION (ID 36)
Room: Hall E
Presenter: James E. Galvin (United States of America)
9:25 – 9:40
THE ADNI4 APPROACH FOR INCREASING DIVERSITY IN AD CLINICAL TRIALS (ID 111)
Room: Hall E
Presenter: Michael Weiner (United States of America)
13:00 – 13:30
Transforming Alzheimer’s Disease Diagnosis with The PrecivityAD2™ Blood Test: Seeking to Establish a New Clinical Care Standard for Patients with Memory Impairment (ID 3284)
Room: Exhibition/Product Theater
Presenter: Joel Braunstein (United States of America)
Thursday, April 3
15:35 – 15:50
PLASMA PTAU217 RATIO PREDICTS THE FUTURE PROGRESSION OF BRAIN TAU ACCUMULATION IN EARLY ALZHEIMER’S DISEASE (ID 1951)
Room: Hall F1
Presenter: Viswanath Devanarayan (United States of America)
Friday, April 4
8:55 – 9:10
EVALUATION OF PLASMA PHOSPHO-TAU217 FOR ALZHEIMER’S DISEASE USING A FULLY AUTOMATED PLATFORM – INTERNATIONAL MULTI-CENTER STUDY IN PRIMARY AND SECONDARY CARE (ID 709)
Room: Hall F2
Presenter: Sebastian Palmqvist (Sweden)
15:35 – 15:50
PRE-RECORDED: EARLY LIFE EXPERIENCES AND CURRENT STRESS INFLUENCE FLUID BIOMARKERS OF ALZHEIMER DISEASE (ID 73)
Room: Hall E
Presenter: John C. Morris (United States of America)
Saturday, April 5
8:40 – 8:55
SMALL MOLECULE TARGETING OF THE P75 NEUROTROPHIN RECEPTOR MODULATES TAU MECHANISMS IN MOUSE AND HUMAN TRIALS (ID 64)
Room: Hall B
Presenter: Frank M. Longo (United States of America)
9:55 – 10:10
MEASUREMENT OF CSF MTBR-TAU243 IN CLINICAL TRIALS OF ALZHEIMER’S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY (ID 3096)
Room: Hall F1
Presenter: Julie Czerkowicz (United States of America)
12:25 – 12:40
PRECIVITYAD2 TEST ACCURATELY IDENTIFIES BRAIN AMYLOID AND TAU PATHOLOGY IN ADNI PARTICIPANTS ENROLLED IN THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH STUDY. (ID 2534)
Room: Hall F2
Presenter: Philip B. Verghese (United States of America)
12:40 – 12:55
CLINICAL TRIAL DESIGN FOR CONCURRENT ANTI-AMYLOID AND ANTI-TAU ANTIBODY THERAPY FOR SPORADIC ALZHEIMER’S DISEASE (ID 2228)
Room: Hall A
Presenter: Thomas Doherty (United Kingdom)
Posters
EVALUATING PLASMA BIOMARKERS AS EARLY PREDICTORS OF AMYLOID AND TAU PET PATHOLOGY IN ALZHEIMER’S DISEASE (ID:3011)
Presenter: Clara Sorensen
A PROSPECTIVE, OBSERVATIONAL STUDY INVESTIGATING THE REAL-WORLD IMPLEMENTATION OF CONFIRMATORY DIAGNOSTIC BLOOD-BASED BIOMARKERS FOR EARLY ALZHEIMER’S DISEASE: A FEASIBILITY ASSESSMENT (ID 1374)
Presenter: Jo Vandercappellen
PREDICTING AMYLOID AND TAU PATHOLOGY WITH PLASMA BIOMARKERS IN ALZHEIMER'S DISEASE (ID 1572)
Presenter: Hanna Cho
HEALTH CARE PROVIDERS’ PERSPECTIVES ON THE REAL-WORLD USE OF CONFIRMATORY DIAGNOSTIC BLOOD-BASED BIOMARKERS FOR EARLY ALZHEIMER’S DISEASE (1753)
Presenter: Jo Vandercappellen
PLASMA AMYLOID PREDICTS AMYLOID ACCUMULATION IN PET A- NON-DEMENTED PARTICIPANTS (2933)
Presenter: Alexandra Gogola
On-Demand Posters
SIMULTANEOUS PREDICTION OF CONTINUOUS BRAIN AMYLOID AND TAU PET LEVELS USING PLASMA PTAU217 RATIO IN PRECLINICAL AND EARLY ALZHEIMER’S DISEASE (2048)
Presenter: Viswanath Devanarayan
Please stop by Booth #14 (head to the right when entering the main exhibit hall entrance) to meet with our medical educators and business development professionals.
We look forward to seeing you in Vienna!
About C2N Diagnostics, LLC
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.